Queremos ser el Uber de la salud. Transformar un sector offline como el de la sanidad en otro 2.0, como ha ocurrido ya en otras industrias como la del transporte o la de turismo, con iniciativas como Uber o Airbnb que han dado más poder al usuario. Nosotros queremos conquistar al paciente del siglo XXI, una persona mucho más informada y que quiere tener más poder sobre su salud”. Este es el objetivo que persigue SaludOnNet, una joven empresa que se ha propuesto universalizar y democratizar la sanidad privada en España. “Queremos que la gente pueda disfrutar de las ventajas de la medicina privada, pero sin tener que contratar un seguro anual de salud.
The U.S. Food and Drug Administration (FDA) has granted commercial clearance for the CerêveTM Sleep System, a prescription device that reduces latency to Stage 1 and Stage 2 sleep for people with insomnia.
Last summer a friend of Marni Mandell was diagnosed with ovarian cancer.
“I knew I wanted to help her, I just didn’t know how,” Mandell said in an interview. “I knew there had to be a way to help that went beyond dropping off meals, but I couldn’t find a service that was helpful in letting me know what was needed.”
Every year in the United States, about 150,000 patients with heart failure undergo surgery to have cardiac resynchronization therapy (CRT) devices implanted. These send regular jolts of electricity through their hearts to keep the chambers pumping in unison. However, about 50,000 of those people will receive no benefit from this invasive and expensive procedure—and find that they have few options left to keep them alive.
La multinacional de hemoderivados Grifols prevé invertir 1.200 millones de euros hasta 2020, de los que gran parte se destinarán a la división de biociencia. Así lo ha anunciado en la presentación que la empresa ha hecho este jueves en la reunión de analistas e inversores en Dublín (Irlanda).
El próximo viernes, 17 de junio, se celebra el primer congreso en Madrid destinado a la Experiencia del Paciente. Una interesante jornada que cuenta con el patrocinio de MONDRAGON Health y que servirá para conocer los últimos avances de salud centrados en la experiencia del usuario; el cuidado, la comunicación y la capacidad de respuesta del personal sanitario.
Inside the glistening red cave of the patient’s abdomen, surgeon Michael Stifelman carefully guides two robotic arms to tie knots in a piece of thread. He manipulates a third arm to drive a suturing needle through the fleshy mass of the patient’s kidney, stitching together the hole where a tumor used to be. The final arm holds the endoscope that streams visuals to Stifelman’s display screens. Each arm enters the body through a tiny incision about 5 millimeters wide.
With the myBIO 2016 healthcare conference in San Francisco coming up June 6 to June 9, we used the CB Insights database to highlight a few early-stage companies exhibiting that are tackling interesting problems.
We scraped the exhibitor page on the event website and created a public list on the CB Insights database that includes funding and performance information for each of the companies we matched. We identified 11 seed/Series A companies that have not yet raised a Series B working across different spaces including the microbiome, virtual reality therapy, and novel cancer diagnostics.
The FDA ended a busy week by giving a thumbs-up late Friday to obeticholic acid as a treatment for primary biliary cirrhosis, a rare disease in which a patient’s own immune system attacks the liver.
Earlier this year, consulting firm Frost & Sullivan predicted that artificial intelligence in healthcare will see a “dramatic market expansion” in the next couple of years, with the potential to reduce the cost of medical treatments by half across the board.
“By 2025, AI systems could be involved in everything from population health management, to digital avatars capable of answering specific patient queries,” said Harpreet Singh Buttar, an analyst at Frost & Sullivan.
